论文部分内容阅读
目的:探讨ESHAP方案对复发性非霍奇金淋巴瘤的疗效。方法:对2008年5月～2011年3月在我科住院的10例复发性非霍奇金淋巴瘤采用ESHAP方案治疗。结果:3例复发性NHL患者达完全缓解(CR率为30%),4例达部分缓解(PR率为40%),总有效率为70%,其中生存最长者43个月,仍处于CR期。毒副作用主要为消化道症状、轻度肝功能异常以及骨髓抑制。结论:ESHAP方案对部分复发性NHL患者仍有效,毒副作用可以耐受,可用于治疗对其他化疗方案无效的复发性NHL。
Objective: To investigate the efficacy of ESHAP regimen in recurrent non-Hodgkin’s lymphoma. METHODS: Ten patients with recurrent non-Hodgkin’s lymphoma who were hospitalized in our department from May 2008 to March 2011 were treated with ESHAP regimen. Results: Three patients with recurrent NHL achieved complete remission (CR rate was 30%), 4 patients achieved partial response (PR rate was 40%), and the total effective rate was 70%. The longest survival time was 43 months and remained at CR period. The main side effects of gastrointestinal symptoms, mild liver dysfunction and bone marrow suppression. Conclusion: The ESHAP regimen is still effective for some patients with recurrent NHL. The toxic side effects can be tolerated. It can be used to treat recurrent NHL that is ineffective for other chemotherapy regimens.